The rise of Viagra initially sparked a surge for pharma, but recent developments present a uncertain scenario for shareholders. Generic versions are reducing earnings, and persistent legal battles add additional risk https://hamzalwje516911.tribunablog.com/sildenafil-and-pharma-a-precarious-play-55828174